Giorgia Guglielmi
Giorgia Guglielmi is a freelance science writer based in Basel, Switzerland. Specializing in life sciences, medicine, and the relationship between science and society, she has published numerous articles in outlets including Nature, Science, and Scientific American. She holds a PhD in biology from the European Molecular Biology Laboratory and a Master’s in Science Writing from the Massachusetts Institute of Technology. She has received recognition for her work, including the John Kendrew Award in 2020 and an ERC-funded FRONTIERS Media Fellowship in 2025. She has also led lectures and workshops on science communication at institutions such as Harvard University and the University of Zurich.
A healthy, diverse gut microbiota is important for mounting strong and lasting immune responses to vaccination.
A recent study highlights the potential for dietary interventions in treating C. difficile infection and inflammatory conditions such as inflammatory bowel disease.
Modifying the microbiota could influence multiple sclerosis progression and provide new therapeutic targets.
Gut microbes adapt to exercise demands, favoring energy production over bacterial diversity.
Targeting TudS could be a potential therapeutic approach for treating C. difficile infections.
Each Fusobacterium nucleatum population has unique traits and distribution patterns across body sites and conditions such as colorectal cancer and Crohn’s disease.
Gut microbiota-produced bile acids can be used as therapeutic targets for multiple sclerosis.
Targeting E. lenta or boosting neutrophil function may lead to new treatment strategies for bronchiectasis and related lung diseases.
Nutrient competition is the main mechanism of C. difficile inhibition, hinting at the potential for targeted therapies with probiotics instead of traditional FMT.
Introducing more natural microbes could improve astronauts’ health.
